{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:49:56Z","timestamp":1791362996988,"version":"4.3.1"},"reference-count":52,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of Shandong Province","award":["ZR2023MH056"],"award-info":[{"award-number":["ZR2023MH056"]}]},{"name":"Qingdao Medical Scientific Research Guidance Program","award":["2022-WJZD188"],"award-info":[{"award-number":["2022-WJZD188"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunogenic cell death (ICD) is a potential mechanism that mediates adaptive immune responses during anticancer therapy. However, expression patterns and clinical implications of ICD related genes in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC) remain unclear. This study aimed to investigate the associations of 34 ICD related genes with immune characteristics, prognosis, and immune checkpoint blocking (ICB) efficacy in CESC and to predict drug responses across different risk subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Ribonucleic acid sequencing (RNA-seq) transcriptomic profiles, standard normalized variate (SNV) data, and corresponding clinicopathological information were retrieved from The Cancer Genome Atlas (TCGA). Consensus clustering was applied to identify two ICD related molecular subtypes. A prognostic signature was constructed using least absolute shrinkage and selection operator (LASSO) Cox regression and validated using immunohistochemistry (IHC) and receiver operating characteristic (ROC) curve analyses. Immunotherapy responses were predicted based on the risk score of the established model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ICD-high subtype (C2) was associated with favorable clinical outcomes and enhanced immune activation. The prognostic signature comprised six genes: ATG5, FOXP3, IFNG, IL1B, PDIA3, and TNF. IHC confirmed higher expression of ATG5 and PDIA3 in cervical cancer (CC) tissues than in normal cervical tissues, and ROC curves verified the predictive accuracy. Furthermore, immunophenoscore (IPS) and tumor immune dysfunction and exclusion (TIDE) scores suggested that low risk patients exhibited better responses to anti programmed cell death protein-1 (PD-1) immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study characterized the expression profiles of ICD related genes and established a novel ICD based classification system for CESC. Comprehensive analyses of the tumor immune microenvironment further validated the capacity of this signature in predicting prognosis and immunotherapy benefits, which may help identify CC patients who are most likely to benefit from immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.21635","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:00:21Z","timestamp":1791360021000},"page":"e21635","source":"Crossref","is-referenced-by-count":0,"title":["Prediction of prognosis and treatment effect of cervical cancer by immunogenic cell death-related genes"],"prefix":"10.7717","volume":"14","author":[{"given":"Xiufang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gynecology, Jiaozhou Hospital Affiliated to Dongfang Hospital of Tongji University, Qingdao, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Luan","sequence":"additional","affiliation":[{"name":"Health Care Department, Qingdao Municipal Hospital, Qingdao, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yewu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"12","key":"10.7717\/peerj.21635\/ref-1","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Molecular Oncology"},{"issue":"1","key":"10.7717\/peerj.21635\/ref-2","doi-asserted-by":"publisher","first-page":"e001926","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"16","key":"10.7717\/peerj.21635\/ref-3","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Current Biology"},{"issue":"21","key":"10.7717\/peerj.21635\/ref-4","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1158\/1078-0432.Ccr-22-0618","article-title":"FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma","volume":"28","author":"Baines","year":"2022","journal-title":"Clinical Cancer Research"},{"key":"10.7717\/peerj.21635\/ref-5","doi-asserted-by":"publisher","first-page":"e85776","DOI":"10.7759\/cureus.85776","article-title":"Immunogenic cell death as a target for combination therapies in solid tumors: a systematic review toward a new paradigm in immuno-oncology","volume":"17","author":"Barjij","year":"2025","journal-title":"Cureus"},{"issue":"10","key":"10.7717\/peerj.21635\/ref-6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/s1470-2045(20)30433-2","article-title":"Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond)","volume":"21","author":"Bersanelli","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"5","key":"10.7717\/peerj.21635\/ref-7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nature Medicine"},{"issue":"23","key":"10.7717\/peerj.21635\/ref-8","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.21037\/atm-20-2656","article-title":"Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer","volume":"8","author":"Borcoman","year":"2020","journal-title":"Annals of Translational Medicine"},{"issue":"3","key":"10.7717\/peerj.21635\/ref-9","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"3","key":"10.7717\/peerj.21635\/ref-10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cbf.3784","article-title":"Inhibition of CD73 expression or A2AR blockade reduces MRP1 expression and increases the sensitivity of cervical cancer cells to cisplatin","volume":"41","author":"Carrera-Mart\u00ednez","year":"2023","journal-title":"Cell Biochemistry and Function"},{"key":"10.7717\/peerj.21635\/ref-11","doi-asserted-by":"publisher","first-page":"629350","DOI":"10.3389\/fonc.2021.629350","article-title":"CXCL10 produced by HPV-positive cervical cancer cells stimulates exosomal PDL1 expression by fibroblasts via CXCR3 and JAK-STAT pathways","volume":"11","author":"Chen","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.7717\/peerj.21635\/ref-12","doi-asserted-by":"publisher","first-page":"107151","DOI":"10.1016\/j.compbiomed.2023.107151","article-title":"Integrated immunological analysis of single-cell and bulky tissue transcriptomes reveals the role of interactions between M0 macrophages and na\u00efve CD4(+) T cells in the immunosuppressive microenvironment of cervical cancer","volume":"163","author":"Chen","year":"2023","journal-title":"Computers in Biology and Medicine"},{"issue":"14","key":"10.7717\/peerj.21635\/ref-13","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.7150\/thno.21471","article-title":"Genomic analysis of tumor microenvironment immune types across 14 solid cancer types: immunotherapeutic implications","volume":"7","author":"Chen","year":"2017","journal-title":"Theranostics"},{"issue":"8","key":"10.7717\/peerj.21635\/ref-14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nature Immunology"},{"issue":"17","key":"10.7717\/peerj.21635\/ref-15","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/jco.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.21635\/ref-16","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1200\/JCO.2018.36.15_suppl.5522","article-title":"Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study","volume":"36","author":"Chung","year":"2018","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.21635\/ref-17","doi-asserted-by":"publisher","first-page":"728018","DOI":"10.3389\/fonc.2021.728018","article-title":"From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune-enhancing activities in the tumor microenvironment","volume":"11","author":"Fabian","year":"2021","journal-title":"Frontiers in Oncology"},{"key":"10.7717\/peerj.21635\/ref-18","doi-asserted-by":"publisher","first-page":"724172","DOI":"10.3389\/fcell.2021.724172","article-title":"Identification of biomarkers for cervical cancer radiotherapy resistance based on RNA sequencing data","volume":"9","author":"Feng","year":"2021","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"12","key":"10.7717\/peerj.21635\/ref-19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"2","key":"10.7717\/peerj.21635\/ref-20","doi-asserted-by":"publisher","first-page":"e1069938","DOI":"10.1080\/2162402x.2015.1069938","article-title":"Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: a large-scale meta-analysis","volume":"5","author":"Garg","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.7717\/peerj.21635\/ref-21","doi-asserted-by":"publisher","first-page":"849352","DOI":"10.3389\/fonc.2022.849352","article-title":"PD-1\/PD-L1 inhibitors for advanced or metastatic cervical cancer: from bench to bed","volume":"12","author":"Huang","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"14","key":"10.7717\/peerj.21635\/ref-22","doi-asserted-by":"publisher","first-page":"e202219059","DOI":"10.1002\/anie.202219059","article-title":"Akaike\u2019s information criterion for stoichiometry inference of supramolecular complexes","volume":"62","author":"Ikemoto","year":"2023","journal-title":"Angewandte Chemie International Edition England"},{"issue":"10","key":"10.7717\/peerj.21635\/ref-23","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","journal-title":"Nature Medicine"},{"issue":"1","key":"10.7717\/peerj.21635\/ref-24","doi-asserted-by":"publisher","first-page":"9536","DOI":"10.1038\/s41598-020-66449-0","article-title":"The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types","volume":"10","author":"Kim","year":"2020","journal-title":"Scientific Reports"},{"issue":"1","key":"10.7717\/peerj.21635\/ref-25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annual Review of Immunology"},{"key":"10.7717\/peerj.21635\/ref-26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.canlet.2019.11.009","article-title":"Immune cells within the tumor microenvironment: biological functions and roles in cancer immunotherapy","volume":"470","author":"Lei","year":"2020","journal-title":"Cancer Letters"},{"issue":"1","key":"10.7717\/peerj.21635\/ref-27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41420-026-03002-4","article-title":"Programmed cell death in cancer: targeting necroptosis to kill tumor cell","volume":"12","author":"Liang","year":"2026","journal-title":"Cell Death Discovery"},{"issue":"1","key":"10.7717\/peerj.21635\/ref-28","doi-asserted-by":"publisher","first-page":"6842963","DOI":"10.1155\/2020\/6842963","article-title":"Research progress on tumor-associated macrophages and inflammation in cervical cancer","volume":"2020","author":"Liu","year":"2020","journal-title":"Biomed Research International"},{"issue":"1","key":"10.7717\/peerj.21635\/ref-29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Molecular Cancer"},{"issue":"10","key":"10.7717\/peerj.21635\/ref-30","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/s1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"1","key":"10.7717\/peerj.21635\/ref-31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncology"},{"issue":"9","key":"10.7717\/peerj.21635\/ref-32","doi-asserted-by":"publisher","first-page":"e005151","DOI":"10.1136\/jitc-2022-005151","article-title":"T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer","volume":"10","author":"Ni","year":"2022","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"5","key":"10.7717\/peerj.21635\/ref-33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/s1470-2045(24)00088-3","article-title":"Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1\u20132, open-label, multicohort trial","volume":"25","author":"Oaknin","year":"2024","journal-title":"The Lancet Oncology"},{"issue":"6","key":"10.7717\/peerj.21635\/ref-34","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1093\/ajrccm\/aamaf124","article-title":"Cracking the code of immunotherapy resistance in SCLC: molecular insights and emerging solutions","volume":"212","author":"Papavassiliou","year":"2026","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.7717\/peerj.21635\/ref-35","author":"R Core Team","year":"2021","journal-title":"R: a language and environment for statistical computing"},{"key":"10.7717\/peerj.21635\/ref-36","author":"R Core Team","year":"2022a","journal-title":"R: a language and environment for statistical computing"},{"key":"10.7717\/peerj.21635\/ref-37","author":"R Core Team","year":"2022b","journal-title":"R: a language and environment for statistical computing"},{"key":"10.7717\/peerj.21635\/ref-38","author":"R Core Team","year":"2014","journal-title":"R: a language and environment for statistical computing"},{"key":"10.7717\/peerj.21635\/ref-39","first-page":"6599","article-title":"Changes of serum levels of tumor necrosis factor (TNF-\u03b1) and soluble interleukin-2 receptor (SIL 2R) in patients with cervical cancer and their clinical significance","volume":"13","author":"Sha","year":"2021","journal-title":"American Journal of Translational Research"},{"issue":"9","key":"10.7717\/peerj.21635\/ref-40","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1158\/1078-0432.Ccr-20-3901","article-title":"FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10.7717\/peerj.21635\/ref-41","doi-asserted-by":"publisher","first-page":"2219591","DOI":"10.1080\/2162402x.2023.2219591","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in oncology","volume":"12","author":"Sprooten","year":"2023","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.7717\/peerj.21635\/ref-42","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncology"},{"key":"10.7717\/peerj.21635\/ref-43","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1021\/acsami.9b23084","article-title":"Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR\/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics-induced immunogenic cell death","volume":"12","author":"Tu","year":"2020","journal-title":"ACS Applied Materials & Interfaces"},{"issue":"3\u20134","key":"10.7717\/peerj.21635\/ref-44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10354-021-00907-w","article-title":"Interleukin 10 rs1800896 and interleukin 1B rs16944 polymorphisms and the risk of cervical cancer","volume":"173","author":"Wagner","year":"2023","journal-title":"Wiener Medizinische Wochenschrift"},{"key":"10.7717\/peerj.21635\/ref-45","doi-asserted-by":"publisher","first-page":"1061107","DOI":"10.3389\/fgene.2022.1061107","article-title":"Immune infiltration and a necroptosis-related gene signature for predicting the prognosis of patients with cervical cancer","volume":"13","author":"Xing","year":"2022","journal-title":"Frontiers in Genetics"},{"issue":"7","key":"10.7717\/peerj.21635\/ref-46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41401-020-0417-3","article-title":"Nanoengineered targeting strategy for cancer immunotherapy","volume":"41","author":"Yin","year":"2020","journal-title":"Acta Pharmacologica Sinica"},{"issue":"16","key":"10.7717\/peerj.21635\/ref-47","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/jco.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"10.7717\/peerj.21635\/ref-48","doi-asserted-by":"publisher","first-page":"4382645","DOI":"10.1155\/2022\/4382645","article-title":"Expression and prognostic significance of PDIA3 in cervical cancer","volume":"2022","author":"Zhang","year":"2022","journal-title":"International Journal of Genomics"},{"key":"10.7717\/peerj.21635\/ref-49","doi-asserted-by":"publisher","first-page":"672356","DOI":"10.3389\/fimmu.2021.672356","article-title":"Neoantigen: a new breakthrough in tumor immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"14","key":"10.7717\/peerj.21635\/ref-50","doi-asserted-by":"publisher","first-page":"e1805888","DOI":"10.1002\/adma.201805888","article-title":"Tumor microenvironment-activatable prodrug vesicles for nanoenabled cancer chemoimmunotherapy combining immunogenic cell death induction and CD47 blockade","volume":"31","author":"Zhou","year":"2019","journal-title":"Advanced Materials"},{"key":"10.7717\/peerj.21635\/ref-51","doi-asserted-by":"publisher","first-page":"757184","DOI":"10.3389\/fcell.2021.757184","article-title":"Increased ATG5 expression predicts poor prognosis and promotes EMT in cervical carcinoma","volume":"9","author":"Zhou","year":"2021","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"9","key":"10.7717\/peerj.21635\/ref-52","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1021\/acs.accounts.0c00254","article-title":"Smart nanosized drug delivery systems inducing immunogenic cell death for combination with cancer immunotherapy","volume":"53","author":"Zhou","year":"2020","journal-title":"Accounts of Chemical Research"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/21635.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/21635.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/21635.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/21635.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:00:25Z","timestamp":1791360025000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/21635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":52,"alternative-id":["10.7717\/peerj.21635"],"URL":"https:\/\/doi.org\/10.7717\/peerj.21635","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"e21635"}}